Absci Corp (ABSI) - Total Assets
Based on the latest financial reports, Absci Corp (ABSI) holds total assets worth $195.59 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Absci Corp - Total Assets Trend (2019–2025)
This chart illustrates how Absci Corp's total assets have evolved over time, based on quarterly financial data. Also see Absci Corp (ABSI) market capitalisation for the company's overall valuation and market capitalisation.
Absci Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Absci Corp's total assets of $195.59 Million consist of 69.2% current assets and 30.9% non-current assets. Review debt load of Absci Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $41.51 Million | 19.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Absci Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Absci Corp (ABSI) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Absci Corp's current assets represent 69.2% of total assets in 2025, a decrease from 70.1% in 2019.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, down from 67.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 19.2% of total assets.
Absci Corp Competitors by Total Assets
Key competitors of Absci Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Absci Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.59 | 5.72 | 3.78 |
| Quick Ratio | 6.59 | 5.72 | 3.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $111.94 Million | $128.70 Million | $82.63 Million |
Absci Corp - Advanced Valuation Insights
This section examines the relationship between Absci Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.88 |
| Latest Market Cap to Assets Ratio | 6.22 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | $216.30 Million |
| Market Capitalization | $1.35 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Absci Corp's assets at a significant premium (6.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Absci Corp's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Absci Corp (2019–2025)
The table below shows the annual total assets of Absci Corp from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $216.30 Million | +1.26% |
| 2024-12-31 | $213.61 Million | -1.70% |
| 2023-12-31 | $217.30 Million | -32.31% |
| 2022-12-31 | $321.01 Million | -24.68% |
| 2021-12-31 | $426.19 Million | +381.20% |
| 2020-12-31 | $88.57 Million | +354.88% |
| 2019-12-31 | $19.47 Million | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more